Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker EBV DNA
NCT02135042Phase 3Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Jul 2014
- Primary completion
- Jan 2029
- Modality
- Cytokines & Interferons, Small Molecules, Fc-Fusion Proteins
- Countries
- 8
01
Overview
A Phase 3 trial of gemcitabine, Paclitaxel Micelles for Injection in nasopharyngeal carcinoma (NPC), sponsored by NRG Oncology. Started Jul 2014; status: active, not recruiting.
02
Drugs
gemcitabinePaclitaxel Micelles for Injection
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02135042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02135042.